DETERMINATION OF DAZOLINYLHYDRAZONE)-2-PHENYLIMIDAZO[1,2-A]PYRIDINE IN PLASMA AND WHOLE-BLOOD BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY

A selective and sensitive HPLC assay for the quantitative determinatio n of a new antifilarial drug, 6,4'-bis-(2-imidazolinylhydrazone)-2-phe nylimidazo [1,2-a]pyridine (CDR 101) is described. After extraction fr om plasma and blood, CDR 101 was analysed using a C-18 Nucleosil ODS c olumn (250 x 4.6 mm, 5 mu m particle size) and mobile phase of acetoni trile-0.05 M ammonium acetate adjusted to pH 3.0, with UV detection at 318 nm. The mean recoveries of CDR 101 in plasma and blood over a con centration range of 25-500 ng/ml were 95.5 +/- 2.01% and 83.3 +/- 1.87 %, respectively. The within-day and day-to-day coefficient of variatio ns for plasma were 3.23-6.21% and 2.59-9.90%, respectively, those for blood were 2.59-5.92% and 2.89-6.82%, respectively. The minimum detect able concentration for CDR 101 was 1 ng/ml in plasma and 2.5 ng/ml in whole blood. This method was found to be suitable for clinical pharmac okinetic studies.